已收盤 03-04 16:00:00 美东时间
0.000
0.00%
Retension Pharmaceuticals completed its IPO in October 2026, raising $51.75 million to support the development of RTN-001 for uncontrolled hypertension. The Phase 2b clinical trial is ongoing, with topline data expected in early 2027. The company has strengthened its leadership team and formed a Scientific Advisory Board of hypertension experts. Third-quarter 2026 financials showed a net loss of $5.9 million, with increased R&D and G&A expenses d...
11-18 13:00
Processa Pharmaceuticals announced FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria (CSU), with additional Phase 2 studies planned for food allergy and relapsing multiple sclerosis. The company expanded its pipeline through a collaboration with Generian Pharmaceuticals for a novel neonatal Fc receptor antagonist program. Sheila Gujrathi, M.D., was appointed Executive Chair of the Board of Directors, and the company ex...
10-29 12:00
文|《财经》记者 凌馨 研究员 丁宁 编辑 | 王小 替尔泊肽给了礼来寻找下一个增长曲线的底气 2026年8月5日,礼来发布二季度财报...
08-11 11:25
Equillium reported Q1 2026 financial results with $61.3M in cash and plans to initiate a Phase 1 study for EQ504 in mid-2026. Snehal Naik, Ph.D., was appointed Chief Development Officer, bringing extensive experience in immunology and clinical development. EQ504, a potent AhR modulator, showed promising preclinical data supporting its potential for treating ulcerative colitis and other inflammatory diseases. The company also highlighted progress ...
05-13 20:01
礼来正就收购私营生物技术公司Kelonia Therapeutics展开深入谈判,交易估值超过20亿美元。
04-20 07:40
Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a transaction valued at more than $2 billion, The Wall Street Journal reported Sunday, citing people familiar with the di...
04-20 06:08
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.
03-31 22:48